Despite these findings, the FDA has approved PD-L1 biomarker tests as companions to nivolumab for treatment of NSCLC, pembrolizumab for treatment of NSCLC, and atezolimuab for treatment of urothelial carcinoma. Here, CD274 is linked to non-small cell lung carcinoma.